Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue

Cancer Science

Volumn 106, Issue 11, 2015, Pages 1635-1641

  Hida, Tomoyuki ^a,b   Matsumoto, Shinji ^a   Hamasaki, Makoto ^a   Kawahara, Kunimitsu ^c   Tsujimura, Tohru ^d   Hiroshima, Kenzo ^e   Kamei, Toshiaki ^f   Taguchi, Kenichi ^g   Iwasaki, Akinori ^a   Oda, Yoshinao ^b   Honda, Hiroshi ^b   Nabeshima, Kazuki ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e Tokyo Women s Medical University   (Japan)

^f Yamaguchi Grand Medical Center   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

p16; Cytology; Fluorescence in situ hybridization; Malignant pleural mesothelioma; Reactive mesothelial hyperplasia

Indexed keywords

PROTEIN P16; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CELL SURFACE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EFFUSION SMEAR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESOTHELIOMA CELL LINE; MESOTHELIUM; MIDDLE AGED; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; TISSUE SECTION; TUMOR LOCALIZATION; VERY ELDERLY; CHROMOSOME ANALYSIS; DIFFERENTIAL DIAGNOSIS; GENETICS; HYPERPLASIA; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL DISEASES; PLEURAL EFFUSION; PLEURAL NEOPLASMS; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, P16; HUMANS; HYPERPLASIA; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL DISEASES; PLEURAL EFFUSION; PLEURAL NEOPLASMS;

EID: 84983094232     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12769     Document Type: Article

References (32)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-90.
3. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labor and Welfare. Vital Statistics of Japan, 2012. Tokyo, Japan: Health and Welfare Statistics Association, 2014.
4. Dacic S, Kothmaier H, Land S et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 2008; 453: 627-35.
5. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006; 29: 14-9.
6. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
7. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010; 5: 1841-8.
8. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.
9. Husain AN, Colby T, Ordonez N et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013; 137: 647-67.
10. Matsumoto S, Nabeshima K, Kamei T et al. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol 2013; 121: 415-22.
11. Senyiğit A, Bayram H, Babayiğit C et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000; 67: 615-22.
12. Chapman A, Mulrennan S, Ladd B, Muers MF. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008; 63: 435-9.
13. Savic S, Franco N, Grilli B et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010; 138: 137-44.
14. Hwang H, Tse C, Rodriguez S, Grown A, Churg A. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Pathol 2014; 38: 681-8.
15. Chung CT, Santos Gda C, Hwang DM et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010; 63: 630-4.
16. Kato Y, Tsuta K, Seki K et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20: 215-20.
17. Prins JB, Williamson KA, Kamp MM et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998; 75: 649-53.
18. Cheng JQ, Jhanwar SC, Klein WM et al. P16 alterations and deletion mapping of 9p21-P22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-51.
19. Singhal S, Wiewrodt R, Malden LD et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003; 9: 3080-97.
20. Musti M, Kettunen E, Dragonieri S et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006; 170: 9-15.
21. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003; 9: 2108-13.
22. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003; 99: 51-6.
23. Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011; 135: 619-27.
24. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer Press, 2004.
25. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesothelioma. Mod Pathol 2008; 21: 742-7.
26. Minato H, Kurose N, Fukushima M et al. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol 2014; 141: 85-93.
27. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet 2001; 127: 93-110.
28. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002; 23: 1127-30.
29. Björkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997; 75: 523-7.
30. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995; 11: 511-5.
31. Stahel RA. Malignant pleural mesothelioma: a new standard of care. Lung Cancer 2006; 54: S9-14.
32. Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ. Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol 2007; 35: 498-502.